- Home
- KWR vs BLTE Comparison
KWR vs BLTE Comparison
Compare KWR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWR
- BLTE
- Stock Information
- Founded
- KWR 1918
- BLTE 2018
- Country
- KWR United States
- BLTE United States
- Employees
- KWR N/A
- BLTE N/A
- Industry
- KWR Major Chemicals
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- KWR Industrials
- BLTE Health Care
- Exchange
- KWR Nasdaq
- BLTE Nasdaq
- Market Cap
- KWR 1.8B
- BLTE 1.9B
- IPO Year
- KWR 1985
- BLTE 2022
- Fundamental
- Price
- KWR $103.37
- BLTE $61.10
- Analyst Decision
- KWR Strong Buy
- BLTE Strong Buy
- Analyst Count
- KWR 4
- BLTE 4
- Target Price
- KWR $157.75
- BLTE $96.67
- AVG Volume (30 Days)
- KWR 151.4K
- BLTE 29.7K
- Earning Date
- KWR 05-01-2025
- BLTE 05-14-2025
- Dividend Yield
- KWR 1.87%
- BLTE N/A
- EPS Growth
- KWR N/A
- BLTE N/A
- EPS
- KWR 5.29
- BLTE N/A
- Revenue
- KWR $1,812,841,000.00
- BLTE N/A
- Revenue This Year
- KWR $3.06
- BLTE N/A
- Revenue Next Year
- KWR $5.01
- BLTE N/A
- P/E Ratio
- KWR $19.63
- BLTE N/A
- Revenue Growth
- KWR N/A
- BLTE N/A
- 52 Week Low
- KWR $95.91
- BLTE $40.00
- 52 Week High
- KWR $197.03
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- KWR 42.34
- BLTE 51.45
- Support Level
- KWR $99.18
- BLTE $59.04
- Resistance Level
- KWR $107.00
- BLTE $62.55
- Average True Range (ATR)
- KWR 3.93
- BLTE 2.51
- MACD
- KWR 0.90
- BLTE 0.32
- Stochastic Oscillator
- KWR 41.57
- BLTE 74.06
About KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.